These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17545705)

  • 1. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.
    Schürmann D; Fätkenheuer G; Reynes J; Michelet C; Raffi F; van Lier J; Caceres M; Keung A; Sansone-Parsons A; Dunkle LM; Hoffmann C
    AIDS; 2007 Jun; 21(10):1293-9. PubMed ID: 17545705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
    Gulick RM; Su Z; Flexner C; Hughes MD; Skolnik PR; Wilkin TJ; Gross R; Krambrink A; Coakley E; Greaves WL; Zolopa A; Reichman R; Godfrey C; Hirsch M; Kuritzkes DR;
    J Infect Dis; 2007 Jul; 196(2):304-12. PubMed ID: 17570119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
    Goebel F; Yakovlev A; Pozniak AL; Vinogradova E; Boogaerts G; Hoetelmans R; de Béthune MP; Peeters M; Woodfall B
    AIDS; 2006 Aug; 20(13):1721-6. PubMed ID: 16931936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection.
    Kümmerle T; Lehmann C; Hartmann P; Wyen C; Fätkenheuer G
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1773-85. PubMed ID: 19888873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.
    Klibanov OM
    Curr Opin Investig Drugs; 2009 Aug; 10(8):845-59. PubMed ID: 19649929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients.
    Pett SL; McCarthy MC; Cooper DA; MacRae K; Tendolkar A; Norris R; Strizki JM; Williams KM; Emery S
    Antivir Ther; 2009; 14(1):111-5. PubMed ID: 19320244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials.
    Caseiro MM; Nelson M; Diaz RS; Gathe J; de Andrade Neto JL; Slim J; Solano A; Netto EM; Mak C; Shen J; Greaves W; Dunkle LM; Vilchez RA; Zeinecker J
    J Infect; 2012 Oct; 65(4):326-35. PubMed ID: 22634184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
    J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.
    Suleiman J; Zingman BS; Diaz RS; Madruga JV; DeJesus E; Slim J; Mak C; Lee E; McCarthy MC; Dunkle LM; Walmsley S
    J Infect Dis; 2010 Feb; 201(4):590-9. PubMed ID: 20064072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
    Currier J; Lazzarin A; Sloan L; Clumeck N; Slims J; McCarty D; Steel H; Kleim JP; Bonny T; Millard J;
    Antivir Ther; 2008; 13(2):297-306. PubMed ID: 18505181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial.
    McNicholas P; Wei Y; Whitcomb J; Greaves W; Black TA; Tremblay CL; Strizki JM
    J Infect Dis; 2010 May; 201(10):1470-80. PubMed ID: 20373959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
    Yeni P; Lamarca A; Berger D; Cimoch P; Lazzarin A; Salvato P; Smaill FM; Teofilo E; Madison SJ; Nichols WG; Adkison KK; Bonny T; Millard J; McCarty D;
    HIV Med; 2009 Feb; 10(2):116-24. PubMed ID: 19200175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.
    Lalezari J; Yadavalli GK; Para M; Richmond G; Dejesus E; Brown SJ; Cai W; Chen C; Zhong J; Novello LA; Lederman MM; Subramanian GM
    J Infect Dis; 2008 Mar; 197(5):721-7. PubMed ID: 18266604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges.
    Lenz JC; Rockstroh JK
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1139-50. PubMed ID: 20712521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.
    Wilkin TJ; Su Z; Krambrink A; Long J; Greaves W; Gross R; Hughes MD; Flexner C; Skolnik PR; Coakley E; Godfrey C; Hirsch M; Kuritzkes DR; Gulick RM
    J Acquir Immune Defic Syndr; 2010 Aug; 54(5):470-6. PubMed ID: 20672447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
    Min S; Sloan L; DeJesus E; Hawkins T; McCurdy L; Song I; Stroder R; Chen S; Underwood M; Fujiwara T; Piscitelli S; Lalezari J
    AIDS; 2011 Sep; 25(14):1737-45. PubMed ID: 21716073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus.
    Uckun FM; Bellomy K; O'Neill K; Messinger Y; Johnson T; Chen CL
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1301-7. PubMed ID: 10565855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disappointing results for vicriviroc.
    AIDS Patient Care STDS; 2010 Mar; 24(3):197-8. PubMed ID: 20238442
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
    Kasserra C; Li J; March B; O'Mara E
    Clin Ther; 2011 Oct; 33(10):1503-14. PubMed ID: 22015327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects.
    Adkison KK; Shachoy-Clark A; Fang L; Lou Y; O'Mara K; Berrey MM; Piscitelli SC
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2802-6. PubMed ID: 15980352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.